Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions
Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesion
MDCECRO LLC
153 participants
Jun 2, 2025
INTERVENTIONAL
Conditions
Summary
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion. A total of 153 subjects will be followed at 1, 6, and 12 months. The primary endpoint is primary patency at 12 months.
Eligibility
Inclusion Criteria8
- (1) Aged 18 to 80 years, regardless of gender. (2) Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3, 4 or 5. (3) Subject (or legal guardian, if applicable) is willing and able to provide consent before to the performance of any study specific tests or procedures, has signed the consent form and agrees to attend all required follow-up visits.
- Eligible subjects must meet all of the following angiographic criteria:
- Stenotic, restenotic or occlusive lesion(s) located in the native superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) (i.e., within the P1 segment):
- Degree of stenosis ≥70% by visual angiographic assessment.
- Vessel diameter ≥4.0 mm and ≤6.5 mm.
- Total lesion length (or series of lesions) ≥ 10 mm and ≤ 140 mm (Note: Lesion segment(s) must be fully covered with one stent).
- Chronic total occlusion with a total lesion length of ≤120 mm.
- Patent popliteal and infrapopliteal arteries, with single-vessel runoff or better, defined as at least one of the three vessels remaining patent (i.e., <50% stenosis) down to the ankle or foot.
Exclusion Criteria18
- Subjects will be excluded from the study if any of the following conditions are present:
- Pregnant or breastfeeding women, or women/men planning to conceive.
- Subjects who have had or are planned for major amputation (at or above the ankle level).
- Subjects known to be allergic or intolerant to materials used in the investigational device or treatment drugs, including nitinol, paclitaxel, aspirin, clopidogrel, heparin, rivaroxaban, contrast agents, etc.
- Subjects with serum creatinine ≥2.5 mg/dL or currently undergoing dialysis.
- Subjects with known, uncorrectable hemorrhagic disorders or severe coagulation dysfunction (prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≥2 times the upper limit of normal, or platelet count <80×10⁹/L).
- Previously stented target lesion/vessel.
- Target lesion/vessel previously treated with drug-coated balloon <12 months prior to enrollment.
- Subjects with a life expectancy of less than 1 year.
- Subjects who have received local or systemic thrombolysis treatment within 48 hours prior to enrollment.
- Subjects diagnosed with major clinical diseases or unstable conditions within the past 3 months, such as severe heart failure, unstable angina, myocardial infarction, transient ischemic attack or stroke, severe neurological or psychiatric history, severe infections, gastrointestinal bleeding, or active disseminated intravascular coagulation.
- Subjects currently participating in another clinical trial involving drugs or medical devices.
- Subjects whom the investigator considers unsuitable for participation in the clinical trial.
- Presence of aneurysm in the target vessel.
- Heavily calcified lesions (Peripheral Arterial Calcium Scoring System \[PACSS\] grades 3-4).
- The target lesion requires the use of plaque excision, laser, or other debulking devices that may damage the vessel intima.
- The guidewire cannot pass through the target lesion, or percutaneous transluminal angioplasty (PTA) balloon cannot be used for pre-dilation.
- Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug-eluting stents (DES) are increasingly used in the treatment of PAD. These stentsare coated with antiproliferative drugs designed to provide mechanical support within the artery while releasing the drug gradually to reduce the risk of restenosis. Commonly used drugs include paclitaxel, sirolimus, and everolimus, which inhibit vascular smooth muscle cell proliferation, thereby reducing the likelihood of re-occlusion.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07122167